HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study
Journal of the International AIDS Society · 2025
DOI: 10.1002/jia2.26523 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von John M Humphrey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV Protease Inhibitors, Guideline Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Introduction
Data on drug resistance, viral outcomes and guidelines compliance following protease inhibitor (PI)‐based second‐line failure in low‐ and middle‐income countries are limited, particularly in the era of dolutegravir‐containing antiretroviral therapy (ART).
Methods
We conducted a retrospective cohort study of people living with HIV (PLWH) ≥3 years old with second‐line viral failure (VF, ≥1000 copies/ml) at the Academic Model Providing Access to Healthcare from 2011 to 2021. We assessed resistance prevalence and patterns at second‐line VF, stratified by PI (atazanavir/ritonavir or lopinavir/ritonavir), and examined correlations of resistance and treatment strategies with VF at 6–18 months post‐genotype. Analyses employed inverse probability weighting, adjusting for calendar year, age, gender, ART duration, PI at genotyping and class‐specific resistance, and considered guidelines‐supported versus unsupported strategies.
Results
Of 187 participants (median age 41 years, 54% female, 41% on atazanavir/ritonavir, 59% on lopinavir/ritonavir‐based ART), 91% had any resistance (NRTI 79%, NNRTI 80%, major PI 37%, dual‐class 36%, triple‐class 37%). Predicted resistance to third‐line options was 67% for etravirine or rilpivirine and 10% for darunavir/ritonavir. Despite higher resistance detected on atazanavir/ritonavir versus lopinavir/ritonavir, predicted darunavir/ritonavir resistance was similar. At median 9 months post‐genotype, 95% of 173 participants with available data were on a guidelines‐supported regimen (55% second‐line; 45% third‐line, 86% dolutegravir‐based), of whom 28% had post‐genotype VF. Of the 5% not on guidelines‐supported regimens, 71% had post‐genotype VF. Adjusted odds of VF were higher for guidelines‐unsupported versus supported regimens (OR = 4.52; 95% CI 1.02−26.24), and odds of VF were 97% lower for those on third‐line versus second‐line (OR = 0.07; 95% CI 0.02−0.20).
Conclusions
We found high levels of drug resistance and early VF following PI‐based second‐line failure in Kenya. Treatment guidelines compliance and switches to third‐line, even within guidelines recommendations, improved early viral outcomes. Findings highlight the vulnerability of PLWH with advanced ART experience and resistance profiles, and the importance of following guidelines and improving access to third‐line and drug resistance testing, particularly in the new ART era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Medicine, Moi University School of Medicine, Eldoret, Kenya.
- Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island, USA.
- Department of Medicine, Brown University Alpert Medical School, Providence, Rhode Island, USA.
- Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
- Department of Pharmacy, Moi Teaching and Referral Hospital, Eldoret, Kenya.
ORCID-Profile: John M Humphrey, Vlad Novitsky, Rami Kantor
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Humphrey, J. M., Ali, S. M., DeLong, A., Novitsky, V., Sang, E., Jawed, B., Kemboi, E., Ngetich, C., Goodrich, S., Gardner, A., Hogan, J. W., & Kantor, R. (2025). HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26523
Vancouver
Humphrey JM, Ali SM, DeLong A, Novitsky V, Sang E, Jawed B, et al. HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26523
BibTeX
@article{Humphrey2025,
author = {Humphrey, John M and Ali, Shamim M and DeLong, Allison and Novitsky, Vlad and Sang, Edwin and Jawed, Bilal and Kemboi, Emmanuel and Ngetich, Celia and Goodrich, Suzanne and Gardner, Adrian and Hogan, Joseph W and Kantor, Rami},
title = {HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study},
journal = {Journal of the International AIDS Society},
year = {2025},
doi = {10.1002/jia2.26523}
}
EUVIMED